Rheumatic Heart DiseasesPRECARE-MAYIANCT07904975
Assessment of the Prevalence of Rheumatic Heart Disease in School Settings in Mayotte and the Acquisition of Ultrasound Sequences Guided by Artificial Intelligence
A study testing Ultrasound performed bycardiologis for diagnosis of rheumatic heart disease in people with Rheumatic Heart Diseases and Scabies, run by Centre Hospitalier Universitaire de la Réunion.
Trial summary
The prevalence of chronic rheumatic heart disease (RHD) on the island of Mayotte is unknown, but it appears to be high and is responsible for significant morbidity and mortality. Read more about this study
- Who is it for?
- Ages 7 to 12 years
- Conditions the study is for
- Rheumatic Heart Diseases, Scabies
- What is being tested?
- Ultrasound performed bycardiologis for diagnosis of rheumatic heart disease
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 900 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2027to 1 Jan 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- pupils:
- In one of 30 fourth-grade classes, selected at random from all fourth-grade classes in the department of Mayotte.
- For whom at least one of the two holders of parental authority has provided consent (no later than the day of inclusion and prior to any examination required by the research).
- Present on the day of the screening and consenting to two ultrasound examinations, each lasting 5 to 20 minutes.
Who cannot join
- Students under guardianship.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The prevalence of chronic rheumatic heart disease (RHD) on the island of Mayotte is unknown, but it appears to be high and is responsible for significant morbidity and mortality. Screening for RHD in schools is currently the only strategy for managing the cardiac complications of the disease; however, it requires trained medical personnel-a resource that is lacking in Mayotte, as is the case in many developing countries where the disease is endemic. RHD is a sequela of *Streptococcus pyogenes* infection, which can originate from tonsillitis or from impetigo secondary to a scabies infestation.
- Conditions
- Rheumatic Heart Diseases, Scabies
- Being tested
- Ultrasound performed bycardiologis for diagnosis of rheumatic heart disease
- Medical subject headings
- Rheumatic Heart Disease, Scabies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ultrasound performed bycardiologis for diagnosis of rheumatic heart diseaseDevice
The following views will be obtained. These include the standard views used for routine screening, plus additional views to screen for common pediatric conditions: parasternal long-axis, parasternal short-axis (aortic level), parasternal short-axis (mitral level), three-chamber, two-chamber, subcostal four-chamber (to screen for an atrial septal defect), parasternal short-axis (at the base), and suprasternal (to screen for a patent ductus arteriosus).
| Study group | Role | What they receive |
|---|---|---|
| Ultrasound performed bycardiologis for diagnosis of rheumatic heart disease | Experimental | Not described Receives: Device: Ultrasound performed bycardiologis for diagnosis of rheumatic heart disease |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of rheumatic heart disease (RHD) among children in the fourth year of primary school (CM1) in the population of Mayotte, based on the screening criteria proposed by the WHF in 2023.
Prevalence of rheumatic heart disease (RHD) among children in the fourth year of primary school (CM1) in the population of Mayotte, based on the screening criteria proposed by the WHF in 2023.
Measured: enrollment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Oct 2026
- Study start1 Oct 2027 (estimated)
- Primary completion1 Jan 2028 (estimated)
- Study completion1 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rheumatic Heart DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 900 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de la Réunion
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07904975
- Sponsor's protocol ID
- 2026/RUN/0002
- Acronym
- PRECARE-MAYIA
- Status last verified
- Oct 2026
- First submitted
- 23 Oct 2026
- Last updated
- 29 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of the Prevalence of Rheumatic Heart Disease in School Settings in Mayotte and the Acquisition of Ultrasound Sequences Guided by Artificial Intelligence
- ClinicalTrials.gov ID
- NCT07904975
- Acronym / sponsor ID
- PRECARE-MAYIA / 2026/RUN/0002
- Conditions
- Rheumatic Heart Diseases, Scabies
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 900 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire de la RéunionUniversity, hospital or other
- Study start
- 1 Oct 2027 (estimated)
- Primary completion
- 1 Jan 2028 (estimated)
- Study completion
- 1 Jan 2028 (estimated)
- First posted
- 29 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The prevalence of chronic rheumatic heart disease (RHD) on the island of Mayotte is unknown, but it appears to be high and is responsible for significant morbidity and mortality. Screening for RHD in schools is currently the only strategy for managing the cardiac complications of the disease; however, it requires trained medical personnel-a resource that is lacking in Mayotte, as is the case in many developing countries where the disease is endemic. RHD is a sequela of *Streptococcus pyogenes* infection, which can originate from tonsillitis or from impetigo secondary to a scabies infestation.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Ultrasound performed bycardiologis for diagnosis of rheumatic heart disease | Experimental | Device: Ultrasound performed bycardiologis for diagnosis of rheumatic heart disease |
Who may qualify
- Ages
- 7 to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (4 listed)
- In one of 30 fourth-grade classes, selected at random from all fourth-grade classes in the department of Mayotte.
- For whom at least one of the two holders of parental authority has provided consent (no later than the day of inclusion and prior to any examination required by the research).
- Present on the day of the screening and consenting to two ultrasound examinations, each lasting 5 to 20 minutes.
Key exclusion criteria (1 listed)
- Students under guardianship.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ultrasound performed bycardiologis for diagnosis of rheumatic heart diseaseThe following views will be obtained. These include the standard views used for routine screening, plus additional views to screen for common pediatric conditions: parasternal long-axis, parasternal short-axis (aortic level), parasternal short-axis (mitral level), three-chamber, two-chamber, subcostal four-chamber (to screen for an atrial septal defect), parasternal short-axis (at the base), and suprasternal (to screen for a patent ductus arteriosus). | Device | Ultrasound performed bycardiologis for diagnosis of rheumatic heart disease |
Primary outcome
Prevalence of rheumatic heart disease (RHD) among children in the fourth year of primary school (CM1) in the population of Mayotte, based on the screening criteria proposed by the WHF in 2023.
Time frame: enrollment
Prevalence of rheumatic heart disease (RHD) among children in the fourth year of primary school (CM1) in the population of Mayotte, based on the screening criteria proposed by the WHF in 2023.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
Related trials for Rheumatic Heart Diseases
Recruiting
Auricular Acupuncture for Autonomic Balance and Pain in Fibromyalgia
Fibromyalgia Syndrome
RecruitingObservational study
Korea VHD Echo Study: Surveillance of Aortic, Mitral & Tricuspid Patients - Insights From Real-world Practice
Heart Valve Diseases, Aortic Valve Stenosis
Not yet recruiting
Effects of Adding Vagal Neuromodulation to Manual Therapy in Women With Fibromyalgia
Fibromyalgia (FM) OR Fibromyalgia Syndrome, Manuel Therapy
Active, not recruitingPhase 2
GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial
Rheumatic Heart Disease
RecruitingObservational study
HRV Variation in Rheumatoid Arthritis
Rheumatoid Arthritis (RA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Ultrasound performed bycardiologis for diagnosis of rheumatic heart disease in people with Rheumatic Heart Diseases and Scabies, run by Centre Hospitalier Universitaire de la Réunion.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact ABASSE, Dr (+262 269 61 80 00, noreply@chmayotte.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of rheumatic heart disease (RHD) among children in the fourth year of primary school (CM1) in the population of Mayotte, based on the screening criteria proposed by the WHF in 2023. (time frame: enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.